Multi institutional retrospective study on clinicopathological significance of serum p53 antibody in the patients with esophageal cancer

Multi institutional retrospective study on clinicopathological significance of serum p53 antibody in the patients with esophageal cancer - Retrospective study of p53 antibody with esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027994

Enrollment

1000

Registered

2017-07-01

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Esophageal cancer undergoing radical surgery (Histological type is not limited to squamous cell carcinoma but is applicable to all esophageal cancer) -More than one year has passed since the operation day until the registration date -Serum p53 antibody level and SCC antigen level measured before treatment

Exclusion criteria

Exclusion criteria: -Active multiple primary cancer (Synchronous or metachronous primary cancer within 5 years without disease-free disease, except that carcinoma in situ or intratumoral carcinoma lesion judged to be cured by topical treatment is active multiple primary cancer not included in cancer)

Design outcomes

Primary

Measure	Time frame
-Tumor marker levels p53 antibody, CEA, SCC antigen, CYFRA 21-1 (CYFRA 21-1 is not essential) -Clinicopathological factors UICC classification before surgery Presence and detail of preoperative treatment and details (chemotherapy, radiation therapy) Presence and detail of postoperative treatment and adjuvant chemotherapy (regimen, radiation therapy) Recurrence site -Lavoratory data (CRP, T-cho, Alb, WBC)	—

Measure

Time frame

-Tumor marker levels p53 antibody, CEA, SCC antigen, CYFRA 21-1 (CYFRA 21-1 is not essential) -Clinicopathological factors *UICC classification before surgery *Presence and detail of preoperative treatment and details (chemotherapy, radiation therapy) *Presence and detail of postoperative treatment and adjuvant chemotherapy (regimen, radiation therapy) *Recurrence site -Lavoratory data (CRP, T-cho, Alb, WBC)

—

Countries

Japan

Contacts

Public ContactHideaki Shimada

Toho University School of Medicine Department of Surgery

eso.marker@ext.toho-u.ac.jp03-3762-4151

Outcome results